Department of Orthopaedic Surgery, Washington University, St. Louis, MO, USA.
Shriners Hospitals for Children - St. Louis, St. Louis, MO, USA.
Methods Mol Biol. 2023;2598:87-114. doi: 10.1007/978-1-0716-2839-3_8.
The generation of large quantities of genetically defined human chondrocytes remains a critical step for the development of tissue engineering strategies for cartilage regeneration and high-throughput drug screening. This protocol describes chondrogenic differentiation of human-induced pluripotent stem cells (hiPSCs), which can undergo genetic modification and the capacity for extensive cell expansion. The hiPSCs are differentiated in a stepwise manner in monolayer through the mesodermal lineage for 12 days using defined growth factors and small molecules. This is followed by 28 days of chondrogenic differentiation in a 3D pellet culture system using transforming growth factor beta 3 and specific compounds to inhibit off-target differentiation. The 6-week protocol results in hiPSC-derived cartilaginous tissue that can be characterized by histology, immunohistochemistry, and gene expression or enzymatically digested to isolate chondrocyte-like cells. Investigators can use this protocol for experiments including genetic engineering, in vitro disease modeling, or tissue engineering.
大量遗传定义的人源软骨细胞的生成仍然是软骨再生组织工程策略和高通量药物筛选发展的关键步骤。本方案描述了人诱导多能干细胞(hiPSC)的软骨分化,hiPSC 可经过基因修饰和广泛的细胞扩增。hiPSC 采用逐步方法在单层中通过中胚层谱系分化 12 天,使用定义的生长因子和小分子。随后在 3D 微球培养系统中进行 28 天的软骨分化,使用转化生长因子β 3 和特定化合物抑制非靶分化。6 周方案可得到 hiPSC 来源的软骨组织,可通过组织学、免疫组织化学和基因表达进行特征分析,或通过酶消化分离出类软骨细胞。研究人员可使用该方案进行包括基因工程、体外疾病建模或组织工程在内的实验。